Australia markets closed

ABBV Jun 2024 230.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.7300-2.1500 (-74.65%)
At close: 01:33PM EST
Full screen
Previous close2.8800
Open0.5700
Bid0.3500
Ask0.7900
Strike230.00
Expiry date2024-06-21
Day's range0.5700 - 0.7300
Contract rangeN/A
Volume2
Open interest14
  • Motley Fool

    2 of the Best Dividend Stocks to Own in 2023

    In either case, it's a good idea to add some dividend stocks to your portfolio. If you want to benefit from passive income and potential growth, I've got two stocks in mind. The stocks I'm talking about also have reached a turning point that could lead to earnings growth down the road.

  • PR Newswire

    Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023

    Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This is a customer centric approach, which supports continued innovation and provides cutting-edge products and technologies to help practitioners and patients' aesthetics needs today and for the future.

  • Motley Fool

    3 Reasons to Buy AbbVie and 2 Reasons Not to Buy

    2023 is expected to be an important year for AbbVie (NYSE: ABBV). The pharmaceutical company is facing its first biosimilar competition in the United States. It's big news because it involves AbbVie's monoclonal antibody blockbuster therapy, Humira, which is on track to generate a second consecutive year of $20 billion-plus in revenue in 2022.